Company intelligence / Profile preview

Inosan Biopharma

Ownership: Private
Employees: ~22
Development stage: Commercial

Overview

Inosan Biopharma has commercially available antivenoms for Sub-Middle East and North African snake bites, Sub-Saharan African snake bites, and Middle East and North African scorpion stings. They have multiple products in various clinical stages, including a Coral Snake Antivenom in Phase III and a North America Anti-Snake Antivenom in registration phase. They also conducted a Phase I clinical trial for anti-SARS-CoV-2 equine antibody F(ab')2 fragments (INOSARS) in patients with mild COVID-19[1][8][10].

Therapeutic areas: OtherInfectious Diseases
Modalities: Antibody-based therapeuticsF(ab')2 Immunoglobulin Fragments (Equine)
Industry: Biotech

Drug pipeline

12 assets

Inoserp Pan-Africa

Unknown

11 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Inosan Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inosan Biopharma.

Explore the full profile